Literature DB >> 433623

Paroxetine: pharmacokinetics, tolerance and depletion of blood 5-HT in man.

J Lund, B Lomholt, J Fabricius, J A Christensen, E Bechgaard.   

Abstract

The tolerance of paroxetine (FG 7051), as well as its pharmacokinetics and reduction of 5-HT in blood, has been investigated in man. Three normal, healthy volunteers were administered the single doses 10, 25, 50, and 75 mg orally, and three volunteers received 10, 25, and 50 mg per day for seven or fourteen days. No toxic effect on blood, kidney, liver, heart or general condition was found by chemical and physical examinations. The pharmacokinetic studies revealed a dose dependent systemic availability, a rather slow elimination (t1-z2 = approximately 16 hrs), a good fit to one compartment open model, and an almost complete metabolism of the substance. 25 mg paroxetine per day gave a maximal reduction of 5-HT in the blood within 2--3 weeks (to approximately 0.03 microgram/ml). The 5-HT levels returned to the basic levels during a three to four weeks drug-free period.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 433623     DOI: 10.1111/j.1600-0773.1979.tb02332.x

Source DB:  PubMed          Journal:  Acta Pharmacol Toxicol (Copenh)        ISSN: 0001-6683


  10 in total

Review 1.  Therapeutic drug monitoring of antidepressants: cost implications and relevance to clinical practice.

Authors:  M J Burke; S H Preskorn
Journal:  Clin Pharmacokinet       Date:  1999-08       Impact factor: 6.447

2.  Cardiovascular (ECG and systolic time intervals) and anticholinergic effects of repeated doses of femoxetine--a comparison with amitriptyline and placebo in healthy men.

Authors:  S J Warrington; P Turner; B K Skrumsager
Journal:  Br J Clin Pharmacol       Date:  1989-03       Impact factor: 4.335

3.  The effect of PK5078, a new serotonin uptake inhibitor, on serotonin levels and uptake in human platelets, following administration to healthy volunteers.

Authors:  M Kenny; T J Lenehan; R Lambe; I Brick; A Darragh; C Maulet
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  EEG and blood level of the potential antidepressant paroxetine after a single oral dose to normal volunteers.

Authors:  G R McClelland; P Raptopoulos
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

5.  Effects of a single oral dose of 3-cyano-imipramine on serotonin uptake and content of platelets in healthy volunteers.

Authors:  M Kenny; T J Lenehan; R Lambe; A Darragh; I Brick; L M Omer
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

6.  Acute and subacute effects on psychomotor performance of femoxetine alone and with alcohol.

Authors:  C Strömberg; M J Mattila
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 7.  Pharmacokinetic optimisation of therapy with newer antidepressants.

Authors:  P J Goodnick
Journal:  Clin Pharmacokinet       Date:  1994-10       Impact factor: 6.447

8.  The role of 5-HT1A receptors in mediating acute negative effects of antidepressants: implications in pediatric depression.

Authors:  K A Rahn; Y-J Cao; C W Hendrix; A I Kaplin
Journal:  Transl Psychiatry       Date:  2015-05-05       Impact factor: 6.222

9.  Paroxetine increases delta opioid responsiveness in sensory neurons.

Authors:  Allison Doyle Brackley; Nathaniel A Jeske
Journal:  eNeuro       Date:  2022-07-25

10.  Intermolecular [3+3] ring expansion of aziridines to dehydropiperi-dines through the intermediacy of aziridinium ylides.

Authors:  Josephine Eshon; Kate A Nicastri; Steven C Schmid; William T Raskopf; Ilia A Guzei; Israel Fernández; Jennifer M Schomaker
Journal:  Nat Commun       Date:  2020-03-09       Impact factor: 14.919

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.